Literatur
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121–131
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132–1142
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2021) S3-Leitlinie Prostatakarzinom L. AWMF Registernummer 043/022OL
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366
Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU (2020) Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol 17(3):168–182
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):4078–4101
UK SABR Consortium (2019) Stereotactic ablative body radiation therapy (SABR): a resource UK SABR consortium (v.6.1)
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74(4):455–462
O’Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC et al (2017) A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology 102:164–172
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 162(2):454
Linxweiler J, Hajili T, Zeuschner P, Menger MD, Stöckle M, Junker K et al (2022) Primary tumor resection decelerates disease progression in an orthotopic mouse model of metastatic prostate cancer. Cancers (Basel) 14(3):737
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15–25
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208–1216
Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX et al (2021) Oligometastatic disease detection with (68)Ga-PSMA-11 PET/CT in hormone-sensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical. Impact Cancers (Basel) 13(19):4982
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Borkowetz gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Die Zusammenfassung ist eine Übersetzung des Abstracts der Originalpublikation
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Borkowetz, A. Behandlung von Oligometastasen durch stereotaktisch-ablative Strahlentherapie oder Resektion beim metastasierten hormonsensitiven Prostatakarzinom. Urologie 61, 770–774 (2022). https://doi.org/10.1007/s00120-022-01861-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-022-01861-0